Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
PURPOSE: The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME). DESIGN: The BOULEVARD trial (ClinicalTrials.gov identifier, NCT02699450) was a prospective, randomized, active comparator-controlled, double-masked, multicenter, phase 2 study conducted at 59 sites in the United States. PARTICIPANTS: The trial enrolled patients 18 years of age or older with center-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) of 325 μm or more. METHODS: Anti-VEGF treatment-naïve patients were randomized 1:1:1 to intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibizumab, and patients previously treated with anti-VEGF were randomized 1:1 to 6.0 mg faricimab or 0.3 mg ranibizumab. Patients were dosed monthly for 20 weeks, followed by an observation period up to week 36 to assess durability. MAIN OUTCOME MEASURES: The prespecified primary outcome measure was mean change in BCVA from baseline at week 24 for faricimab versus ranibizumab in treatment-naïve patients. Key secondary and exploratory outcome measures included CST, Diabetic Retinopathy Severity Scale (DRSS) score, and durability as assessed by time to re-treatment. RESULTS: The trial enrolled 229 patients (168 treatment-naïve and 61 previously treated with anti-VEGF). In treatment-naïve patients, 6.0 mg faricimab, 1.5 mg faricimab, and 0.3 mg ranibizumab resulted in mean improvements of 13.9, 11.7, and 10.3 ETDRS letters from baseline, respectively. The 6.0-mg faricimab dose demonstrated a statistically significant gain of 3.6 letters over ranibizumab (P = 0.03). In both patient populations, faricimab resulted in dose-dependent reductions in CST, improvements in DRSS score, and longer time to re-treatment during the observation period compared with ranibizumab. Faricimab showed no new or unexpected safety signals. CONCLUSIONS: The BOULEVARD trial met its primary end point; faricimab demonstrated statistically superior visual acuity gains versus ranibizumab at week 24 in treatment-naïve patients. Central subfield thickness reduction, DRSS score improvement, and extended durability outcomes support the primary outcome. These findings suggest the benefit of simultaneous inhibition of angiopoietin-2 and VEGF-A with faricimab for patients with DME.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2007) · Developments in Ophthalmology · doi:10.1159/isbn.978-3-318-01439-6 · Cited by 5,583
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Cheung, N., Mitchell, P., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62124-3 · Cited by 3,288
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., & Qin, Y. (1995) · Nature · doi:10.1038/376070a0 · Cited by 1,820
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Self-citationAflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Ting, D. S. W., Cheung, G. C. M., & Wong, T. Y. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12696 · Cited by 1,066
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.022 · Cited by 1,051
Self-citationTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Self-citationIntravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
Klaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0493 · Cited by 720
Fong, D. S., Aiello, L. P., Ferris, F. L., & Klein, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2540 · Cited by 640
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Molecular pathogenesis of retinal and choroidal vascular diseases
Campochiaro, P. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.002 · Cited by 545
Oh, H., Takagi, H., Suzuma, K., Otani, A., Matsumura, M., & Honda, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15732 · Cited by 499
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468
Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory
Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., Lopez-Galvez, M., Navarro-Gil, R., & Verges, R. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2156273 · Cited by 404
Regula, J. T., Lundh von Leithner, P., Foxton, R., Barathi, V. A., Cheung, C. M. G., Bo Tun, S. B., Wey, Y. S., Iwata, D., Dostalek, M., Moelleken, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505889 · Cited by 376
Self-citationAngiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation
Scholz, A., Plate, K. H., & Reiss, Y. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12726 · Cited by 248
Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
Gerald, D., Chintharlapalli, S., Augustin, H. G., & Benjamin, L. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4697 · Cited by 202
Anti-vascular endothelial growth factor therapy for diabetic macular edema
Boyer, D. S., Hopkins, J. J., Sorof, J., & Ehrlich, J. S. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813512360 · Cited by 193
Rangasamy, S., Srinivasan, R., Maestas, J., McGuire, P. G., & Das, A. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6386 · Cited by 177
Ciulla, T. A., Bracha, P., Pollack, J., & Williams, D. F. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.06.004 · Cited by 162
Angiopoietin 2 Induces Pericyte Apoptosis via α3β1 Integrin Signaling in Diabetic Retinopathy
Park, S. W., Yun, J.-H., Kim, J. H., Kim, K.-W., Cho, C.-H., & Kim, J. H. (2014) · Diabetes · doi:10.2337/db13-1942 · Cited by 156
Diabetic Retinopathy and Diabetic Macular Edema
Cohen, S. R., & Gardner, T. W. (2015) · Developments in ophthalmology · doi:10.1159/000438970 · Cited by 141
Holekamp, N. M., Campbell, J. H., Almony, A., Ingraham, H. J., Marks, S. J., Chandwani, H. S., Cole, A. L., & Kiss, S. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.04.010 · Cited by 108
Fuxe, J., Tabruyn, S. P., Colton, K., Zaid, H. B., Adams, A., Bałuk, P., Lashnits, E. W., Morisada, T., Le, T., O’Brien, S., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.02.008 · Cited by 94
Dugel, P. U., Hillenkamp, J., Sivaprasad, S., Voegeler, J., Mousseau, M., Wenzel, A., Margaron, P., Hashmonay, R., & Massin, P. (2016) · Clinical ophthalmology · doi:10.2147/opth.s100764 · Cited by 84
Self-citationChakravarthy, U., Bailey, C., Brown, D., Campochiaro, P., Chittum, M., Csaky, K., Tufail, A., Yates, P., Cech, P., Giraudon, M., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.003 · Cited by 82
Self-citationOcular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors
Rubio, R. G., & Adamis, A. P. (2016) · Developments in Ophthalmology · doi:10.1159/000431129 · Cited by 62
Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina
Lee, S. G., Lee, C.-G., Yun, I. H., Hur, D. Y., Yang, J. W., & Kim, H. W. (2011) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2011.02695.x · Cited by 41
Foxton, R. H., Uhles, S., Gruener, S., et al. (2018) · Investigative Ophthalmology & Visual Science · Cited by 3
Cited by
Wykoff, C. C., Abreu, F., Adamis, A. P., Basu, K., Eichenbaum, D. A., Haskova, Z., Lin, H., Loewenstein, A., Mohan, S., Pearce, I. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00018-6 · Cited by 504
Self-citationPredicting conversion to wet age-related macular degeneration using deep learning
Yim, J., Chopra, R., Spitz, T., Winkens, J., Obika, A., Kelly, C., Askham, H., Lukic, M., Huemer, J., Fasler, K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0867-7 · Cited by 297
Joussen, A. M., Ricci, F., Paris, L. P., Korn, C., Quezada-Ruiz, C., & Zarbin, M. (2021) · Eye · doi:10.1038/s41433-020-01377-x · Cited by 290
Xu, G.-T., Zhang, J.-F., & Tang, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.355743 · Cited by 280
Khanani, A. M., Patel, S. S., Ferrone, P. J., Osborne, A., Sahni, J., Grzeschik, S., Basu, K., Ehrlich, J. S., Haskova, Z., & Dugel, P. U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2699 · Cited by 183
Self-citation
Metadata
- Authors
- Sahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., Osborne, A., Weikert, R., & Fauser, S.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 126
- Issue
- 8
- Pages
- 1155-1170
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2924771381
- Cited by
- 285
- References
- 39
- FWCI
- 26.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.